Mindset Pharma Expands Benchmarking Data for First Generation Psychedelics Through the COPE Program with InterVivo Solutions
Mindset Pharma (MSET) is rapidly expanding its pipeline thanks to advancements made by its Co-operative Psychedelics Evaluation (COPE) program, which aims to develop preclinical benchmark data for psychedelic medicines.
Researchers established standard pharmacokinetic, brain penetration, and drug discrimination data and protocols for psilocybin, LSD, and 5-MeO-DMT. The company also developed procedures to determine concentrations of the drugs in plasma, brain, and cerebral spinal fluid.
These finding, which were gathered in collaboration with InterVivo Solutions, will help drug developers understand how compounds interact with the body. Mindset will commercialize the data by making it available to other InterVivo clients.